



AGENDA

Reimbursement-Era Treatment Strategies for **BRAF V600E Mutant mCRC**

APR 18 Sat. 台北六福萬怡 7樓 超新星廳



點擊報名



加入行事曆

主辦單位



中華民國大腸直腸外科醫學會
SOCIETY OF COLON-ANORECTAL SURGEONS, TAIWAN

協辦單位



LABORATOIRES
Pierre Fabre

學分申請中

外科醫學會
癌症醫學會
消化外科醫學會
臨床腫瘤醫學會
大腸直腸外科醫學會

Time	Topic	Speaker	Moderator
14:00-14:30	Registration		
14:30-14:40	Opening		陳自諒 醫師 新竹中國
14:40-15:10	From Cytotoxic to Targeted: The Evolution of mCRC Management	鄧豪偉 醫師 台北榮總	張世慶 醫師 台北榮總
15:10-15:40	Precision Oncology in mCRC: Targeting the BRAF V600E Subtype	張伸吉 醫師 中國附醫	柯道維 醫師 中國附醫
15:40-15:50	Ceremony		
15:50-16:00	Break		
16:00-16:30	Real-World Application of Encorafenib-Based Therapy	黃國埕 醫師 和信醫院	林炯森 醫師 台北馬偕
16:30-17:00	Beyond Reimbursement: What's the optimizing strategy in new era?	梁逸歆 醫師 臺大醫院	林本仁 醫師 臺大醫院
17:00-17:20	Panel Discussion	梁逸歆 醫師 陳明晃 醫師 臺大醫院 台北榮總	陳自諒 醫師 新竹中國
		徐鴻智 醫師 張沛泓 醫師 林口長庚 基隆長庚	王照元 醫師 高醫附醫
17:20-17:30	Closing		王照元 醫師 高醫附醫

主題：Reimbursement-Era Treatment Strategies for BRAF V600E Mutant mCRC: From Evidence to Clinical Decision Making

時間：2026-04-18 14:00-17:30

地點：台北六福萬怡七樓 超新星廳(台北市南港區忠孝東路七段 359 號，CityLink B 棟)

主辦：中華民國大腸直腸外科醫學會

Abstract (1、2)

Abstract_鄧豪偉醫師_From Cytotoxic to Targeted The Evolution of mCRC Management

From Cytotoxic to Targeted: The Evolution of mCRC Management

Over the past two decades, the treatment landscape of metastatic colorectal cancer (mCRC) has evolved dramatically—from conventional cytotoxic chemotherapy to biologics and, more recently, biomarker-driven precision therapies. Survival outcomes have steadily improved through optimized sequencing strategies and multidisciplinary care. However, not all molecular subtypes derive equal benefit from traditional approaches. The emergence of actionable mutations has redefined treatment paradigms, shifting clinical focus toward individualized strategies. In this session, we will revisit the milestones that have shaped modern mCRC management and examine how molecular stratification has transformed therapeutic algorithms. Understanding this evolution provides essential context for integrating targeted therapies into routine practice, particularly in the reimbursement era where evidence, accessibility, and sustainability must be carefully balanced.

Abstract_張伸吉醫師_Precision Oncology in mCRC Targeting the BRAF V600E Subtype

Precision Oncology in mCRC: Targeting the BRAF V600E Subtype

BRAF V600E mutation represents a distinct and aggressive molecular subtype of mCRC, characterized by poor prognosis and limited responsiveness to conventional chemotherapy. Advances in molecular profiling have enabled more precise identification of this high-risk population, paving the way for rationally designed targeted combinations. Clinical trials have demonstrated meaningful improvements in survival outcomes with BRAF-targeted regimens, redefining standards of care in later-line settings. This session will explore the biological rationale behind BRAF inhibition, key clinical evidence supporting targeted strategies, and the evolving role of precision oncology in optimizing outcomes for this subgroup. As reimbursement reshapes access to innovative therapies, integrating molecular insights into practical treatment sequencing becomes increasingly critical.

主題：Reimbursement-Era Treatment Strategies for BRAF V600E Mutant mCRC: From Evidence to Clinical Decision Making

時間：2026-04-18 14:00-17:30

地點：台北六福萬怡七樓 超新星廳(台北市南港區忠孝東路七段 359 號，CityLink B 棟)

主辦：中華民國大腸直腸外科醫學會

Abstract (3 、 4)

Abstract_黃國埕醫師_Real-World Application of Encorafenib-Based Therapy

Real-World Application of Encorafenib-Based Therapy

While randomized trials establish efficacy, real-world data provide crucial insights into treatment effectiveness, safety, and implementation challenges in daily practice. In Taiwan, increasing clinical experience with encorafenib-based therapy has generated valuable perspectives on patient selection, toxicity management, and outcome optimization. Differences in healthcare systems, reimbursement policies, and patient characteristics can significantly influence therapeutic decision-making. This session will present local real-world evidence and clinical experiences, highlighting practical considerations when incorporating BRAF-targeted therapy into routine care. Understanding how evidence translates beyond clinical trials is essential in the reimbursement era, where balancing guideline recommendations, patient affordability, and institutional policies often shapes final treatment decisions.

Abstract_梁逸歆醫師_Beyond Reimbursement Optimizing Treatment Sequencing in the New Era

Beyond Reimbursement: what's the optimizing strategy in new era?

With the approval and reimbursement of BRAF-targeted therapy in the second-line setting, clinicians now face new strategic considerations regarding optimal sequencing. Emerging first-line data suggests substantial survival benefits with early integration of targeted therapy, raising important discussions about timing, accessibility, and patient-centered decision-making. How should physicians navigate the tension between reimbursed second-line indications and promising first-line evidence? What factors should guide shared decision-making with patients? This session will explore future treatment perspectives, including sequencing strategies, evolving evidence, and ethical considerations in the reimbursement era. Ultimately, our goal is to align clinical innovation with real-world feasibility to maximize long-term survival outcomes for patients with BRAF V600E-mutant mCRC.

鄧豪偉 醫師

Hao-Wei Teng, M.D./ Ph.D.

▲Education:

Bachelor of Medicine, National Yang-Ming University

PhD, Institute of Clinical Medicine, National Yang-Ming University

▲Employment Records:

Attending Physician of Taipei Veterans General Hospital, Department of internal medicine, Oncology.

Professor, National Yang-Ming University

▲Professional Subject:

Hematology, Oncology

Programmer: JAVA/R/JSP/MS-SQL/SAS/SPSS

▲Board Certification:

The board of Taiwan society of internal medicine

The board of medical oncology of the Chinese oncology society

The board of the hematology society of Taiwan

The board of Taiwan society of cancer palliative medicine

▲Societies:

The international society of hematology

The hematology society of Taiwan

Taiwan society of cancer palliative medicine

Taiwan society of internal medicine

Website:



crc.uptocare.com



R 生物資訊互動統計



大腸直腸癌即時照護網 <https://crc.uptocare.com>

皮膚即時照護網 <https://skin.uptocare.com>

癌症統計互動網站 <https://uptocare.shinyapps.io/uptocarestat/>

The website for the Data Integration Project at National Yang Ming Chiao Tung University, Yilan Hospital (2023/10) <https://stat.hosp.nycu.edu.tw/>

Persons per 1 year

張伸吉 醫師

Jeffrey, Sheng-Chi Chang, M.D PhD

▲介紹

張伸吉醫師師承陳自諒教授，精熟各式大腸直腸微創手術後，再遠赴荷蘭 Catharina Ziekenhuis 醫院進行腹膜腫瘤手術暨熱化療進修，並於 2019 年至新加坡 National University 醫院取得「加壓腹膜內氣霧化學療法(PIPAC)」完訓證明。張醫師為人和藹可親，手術經驗豐富，解說詳細，在微創手術上的研究更是首屈一指，尤其專精「大腸直腸癌」及「腹膜惡性腫瘤」的治療，目前也擔任這兩個科室的負責人。

▲專長

- 1.各式大腸直腸癌微創手術
- 2.腹膜腫瘤特殊治療 [腹腔熱化療(HIPEC)、加壓腹膜內氣霧化學療法(PIPAC)]
- 3.各式微創痔瘡手術；微創肛門瘻管手術(雷射瘻管消融)
- 4.大腸直腸癌 細胞免疫治療

▲現職

中國醫藥大學附設醫院 大腸直腸外科主任
中國醫藥大學附設醫院 腹膜腫瘤治療中心主任
中國醫藥大學附設醫院 細胞治療中心副主任
大腸直腸癌團隊副負責人
台灣腹膜腫瘤醫學會理事 及 中華民國傷口醫學會理事

▲學歷

中國醫藥大學 醫學系醫學士
中國醫藥大學 醫學研究所碩士
中興大學 生命科學系 博士

▲經歷

中國醫藥大學附設醫院 大腸直腸外科 主治醫師
中國醫藥大學附設醫院 外科總醫師
荷蘭 Catharina Ziekenhuis 醫院外科研究員

▲研究

微創自然孔手術於大腸直腸癌上的臨床應用
腹腔熱化療於大腸直腸癌的應用與療效
細胞治療於結直腸癌的運用

▲發表論文【提供近期 10 篇】

- 1.Chang SC, et al. Short and long-term outcomes of cytoreductive surgery with hyperthermic intraperitoneal chemotherapy for colorectal and appendiceal cancer peritoneal metastasis: Propensity score-matched comparison between laparoscopy vs. open approaches. Surg Oncol 2022

- 2.Chang SC, et al. Peritoneal contamination and associated post-operative infectious complications after natural orifice specimen extraction for laparoscopic colorectal surgery. Surg Endosc 2022
- 3.Chang SC, et al. Laparoscopic total pelvic peritonectomy for colorectal cancer pelvic carcinomatosis: a retrospective case series and photographic/videographic step-by-step guide. Surg Endosc 2021
- 4.Chang SC, et al. Natural orifice versus conventional mini-laparotomy for specimen extraction after reduced-port laparoscopic surgery for colorectal cancer: propensity score-matched comparative study. Surg Endosc 2021
- 5.Chang SC, et al. Long-term Oncologic Outcomes of Laparoscopic Anterior Resections for Cancer with Natural Orifice versus Conventional Specimen Extraction: A Case-Control Study. Dis Colon Rectum 2020
- 6.Seow-En I, Chang SC, et al. Uncomplicated Sigmoid Volvulus Is Ideal for Laparoscopic Sigmoidectomy With Transrectal Natural Orifice Specimen Extraction. Dis Colon Rectum 2020
- 7.Saurabh B, Chang SC, et al. Natural orifice specimen extraction with single stapling colorectal anastomosis for laparoscopic anterior resection: feasibility, outcomes, and technical considerations. Dis Colon Rectum 2017
- 8.Chang SC, et al. Laparoscopic Excision is an Alternative Method for Rectal Gastrointestinal Stromal Tumor. Surg Laparosc Endosc Percutan Tech 2010
- 9.Chang SC, et al. Experimental Study on Effect of Compounds in Inhibiting HCT-116 Human Colon Cancer Cell: the Preliminary Results. J Soc Colon Rectal Surgeon (Taiwan) 2010
- 10.Chang SC, Chen HH et al. Pleomorphic Liposarcoma of the Scalp: a case report and literature review. J Plast Surg AssoR.O.C 2008; 17: 198-204
- 11.Chen WT, Chang SC, et al. Single-incision Laparoscopic versus Conventional Laparoscopic Right Hemicolectomy: A Comparison of Short-Term Surgical Results. Surgical Endoscopy 2011
- 12.Chen WT, Chang SC et al. Identification of biomarkers to improve diagnostic sensitivity of sporadic colorectal cancer in patients with low preoperative serum carcinoembryonic antigen by clinical proteomic analysis. Clin Chim Acta. 2011
- 13.Seow-En I, Ke TW, Chang SC et al. Laparoscopic retrojejunal trans-mesenteric anastomosis for extended left-sided colorectal resections - a new solution to an old problem. Colorectal Dis. 2021
- 14.Chien A, Yang CC, Chang SC et al. Ultrasound Acupuncture for Oxaliplatin-induced Peripheral Neuropathy in Patients With Colorectal Cancer: A Pilot Study. PM R. 2021
- 15.Chen WT, Bansal S, Chang SC et al. Combined repeat laparoscopy and transanal endoluminal repair (hybrid approach) in the early management of postoperative colorectal anastomotic leaks: technique and outcomes. Surg Endosc. 2018

梁逸歆 醫師

Yi-Hsin Liang, M.D., Ph. D., Assistant professor

Citizenship : Taiwan, the Republic of China (R.O.C.)

Department of Oncology

National Taiwan University Hospital,

No.7, Chung Shan S. Rd. (Zhongshan S. Rd.) ,

Zhongzheng Dist., Taipei City 100, Taiwan (R.O.C.)

E-mail: liangyihsin@ntuh.gov.tw

emperormonarch@gmail.com

Tel: +886-2-23123456#66007

Fax: +886-2-23711174

▲Education

Graduate Institute of Oncology, College of Medicine, National Taiwan University,

(2015/07~2022/01) , Ph. D. awarded on Jan. 2022

Department of Medicine, College of Medicine, National Taiwan University, (1998/07~2005/06) ,

M.D. awarded on June 2005

The Affiliated Senior High School of National Taiwan Normal University (1995/07~1998/06)

▲Postgraduate Training and Positions

Assistant professor, Graduate Institute of Oncology, College of Medicine, National Taiwan University, Taipei, Taiwan, (2023/01~Present)

Attending Physician, Department of Oncology, National Taiwan University Hospital, Taipei, Taiwan, (2016/07~Present)

Chairman, Department of Oncology, National Taiwan University Hospital, Hsinchu Branch, Hsin-Chu, Taiwan, (2015/05~2016/6)

Attending Physician, Department of Oncology, National Taiwan University Hospital, Hsinchu Branch, Hsin-Chu, Taiwan, (2014/07~2016/6)

Adjunct Attending Physician, Department of Oncology, National Taiwan University Hospital, Taipei, Taiwan, (2012/07~2016/6)

Attending Physician, Department of Hemato-Oncology, E-da Hospital, Kaohsiung, Taiwan, (2012/07~2014/06)

Chief Resident, Department of Oncology, National Taiwan University Hospital, Taipei, Taiwan, (2009/07~2012/06)

Resident, Department of Internal Medicine, National Taiwan University Hospital, Taipei, Taiwan, (2006/07~2009/06)

▲Board Certifications

Medical Doctor , 2005-09-14

Board of Internal Medicine , 2009-12-21 , 內專醫字 008306 號

Board of Medical Oncology , 2012-05-05 , 中腫內專醫證字第 00002 號

Board of Taiwan Society of Cancer Palliative Medicine , 2014-10-01 , 癌安專字第 0000000141 號

▲Membership in Societies

Taiwan Medical Association , 2005~Present

Taiwan Society of Internal Medicine , 2009~Present

The Taiwan Oncology Society , 2012~Present

American Society of Clinical Oncology , 2012~Present

Taiwan Society of Cancer Palliative Medicine , 2014~Present

American Association for Cancer Research , 2015~Present

European Society of Medical Oncology , 2016~Present

▲Qualification of Teacher

Clinical Teacher, E-da Hospital, (2013/01~2014/06)

Clinical Teacher, National Taiwan University Hospital, (2016/07~Present)

▲ Publication in Journals 【提供近期 10 篇】

1.Chen CT, Liang YH, Lin BR, Chen KH, Yeh KH. Combination of anti-epidermal growth factor receptor antibodies plus trifluridine-tipiracil as rechallenge strategy improves treatment outcomes in patients with RAS/BRAF wild-type refractory metastatic colorectal cancer. Am J Cancer Res. 2025 Jul 15;15(7):3142-3149.

2.Chang CC, Liang YH, Lin BR, Chen KH, Yeh KH. Metastatic Colon Cancer Recurring After Cetuximab Plus Doublet Chemotherapy Harboring Acquired KRAS G12C Mutant that Responded to Sotorasib Plus Cetuximab. JCO Precis Oncol. 2025 Apr;9:e2400609.

3.Hsieh YY, Su YL, Kuan FC, Chen SG, Chang CL, Shao YY, Tsai CW, Liang YH(Corresponding author). Continuing anti-EGFR monoclonal antibody after secondary resection significantly prolongs overall survival for patients with metastatic colorectal cancer who were responsive to first-line anti-EGFR monoclonal antibody plus chemotherapy doublet. Am J Cancer Res. 2024 Dec 15;14(12):5909-5920. (Corresponding author)

4.Wu TC, Liang YH, Chen KH, Shao YY, Sidedness and addition of chemotherapy associated with treatment outcomes of regorafenib for metastatic colorectal cancer: a population-wide cohort study. ESMO GI Oncology, Volume 4100052June 2024

5.Liang YH, Chen KH, Shao YY. Treatment outcome comparisons of first-line targeted therapy in patients with KRAS wild-type metastatic colorectal cancer: A nationwide database study. Cancer Med. 2023 Jul;12(14):15176-15186

6.Liang YH, Liang JT, Lin BR, Huang J, Hung JS, Lai SL, Chen TC, Tsai JH, Cheng YM, Tsao TH, Hsu WL, Chen KH, Yeh KH. Ramucirumab Plus Triplet Chemotherapy as an Alternative Salvage Treatment for Patients with Metastatic Colorectal Cancer. J Formos Med Assoc. 2022 Mar 11:S0929-6646(22)00100-0.

- 7.Chen HH, Ke TW, Huang CW, Jiang JK, Chen CC, Hsieh YY, Teng HW, Lin BW, Liang YH, Su YL, Hsu HC, Kuan FC, Chou YH, Lin J, Lin BR, Chang YY, Wang JY. Taiwan Society of Colon and Rectal Surgeons Consensus on mCRC Treatment. Front Oncol . 2021 Nov 15;11:764912.
- 8.Liang YH, Chen KH, Tsai JH, Cheng YM, Chan KY, Hsu WL, Lee CC, Chen KH, Yeh KH. Proteasome inhibitors restore the STAT1 pathway and enhance the expression of MHC class I on human colon cancer cells. J Biomed Sci. Nov. 10, 28(1), 75 (2021). doi: 0.1186/s12929-021-00769-9
- 9.Liang YH, Tsai JH, Cheng YM, Chan KY, Hsu WL, Lee CC, Chen KH, Yeh KH. Chemotherapy agents stimulate dendritic cell against human colon cancer cells through upregulation of the transporter associated with antigen processing. Sci Rep. Apr. 27, 11:9080, 2021
- 10.Liang YH, Chan KY, Lee CC, Chen TJ, Cheng AL, Yeh KH. IFN- γ elicits stimulatory MHC class I isotypes in human colorectal carcinoma cell lines with genetic features of microsatellite stable. Cancer Research 78 (13 Supplement), 608-608

黃國埕

Kuo-Cheng Huang

專精於腫瘤內科學，照顧病人以大腸直腸癌、泌尿系腫瘤、甲狀腺癌為主

現職 和信治癌中心醫院 腫瘤內科部 資深主治醫師 2022.07~迄今

專長 大腸直腸癌、泌尿系癌、甲狀腺癌

學歷 陽明大學 醫學系 學士 1994.09~2001.06

經歷 和信治癌中心醫院 內科部血液腫瘤科 專研醫師 2006.07~2009.06

和信治癌中心醫院 內科 住院醫師 2003.08~2006.06

和信治癌中心醫院 血液與腫瘤內科部 主治醫師 2009.07~2022.06

參與學會 台灣內科醫學會、中華民國癌症醫學會